[A Markov model to access long-term effects of rosiglitazone natrium on the treatment of type 2 diabetes].
OBJECTIVE
The aim of this study was to estimate the long-term treatment effects of Rosiglitazone-natrium in type 2 diabetes.


METHODS
A Markov decision model was developed to predict, over 10 years, mortality with or without Rosiglitazone-natrium treatment.


RESULTS
During 10 years research, 14.2% patients developed to complications of type 2 diabetes mellitus, 3.8% patients should be dead in Rosiglitazone-natrium treatment group. 22.7% patients developed to complications of type 2 diabetes, 6.6% patients should be dead in non-Rosiglitazone-natrium treatment group.


CONCLUSIONS
Markov decision model should be useful in accessing the long-term effects of drug treatment. Evidence on long-term benefit of Rosiglitazone-natrium could be of importance for future decision making.
Zhu
Cai-Rong
CR
West China School of Public Health, Sichuan University, Chengdu 610044, China.
Ni
Zong-Zan
ZZ
Sun
Ke-Hong
KH
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008297:Male; D008390:Markov Chains; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D013995:Time
D045162:Thiazolidinediones; D000077154:Rosiglitazone